Familial Mediterranean fever
|
|
- Louisa Curtis
- 5 years ago
- Views:
Transcription
1 Familial Mediterranean fever Is a hereditary autoinflammatory disorder characterized by recurrent bouts of fever and serosal inflammation. The initial attack occurs before the ages of 10 and 20 years in 65 and 90 percent of cases. In rare cases, the initial attack can occur in individuals older than 50 years of age. As the name indicates, FMF occurs within families and is much more common in individuals of Mediterranean descent than in persons of any other ethnicity Epidemiology In adults, FMF is more prevalent in men than in women. It mainly occurs in families of Mediterranean area. Age: 50-60% are younger than 10 years % are younger than 20 years. 5-10% are older than 20 years at onset. Onset in people older than 40 years is rare Pathophysiology Mutations in the MEFV (Mediterranean fever) gene on chromosome 16 appear to cause the disease in many cases. MEFV produces a protein called pyrin (derived from the association with predominant fever); the protein is also called marenostrin (derived from the phrase "our sea," because of the Mediterranean heritage of most patients). Pyrin acts without a known provocation, the outcome of this process is secretion of interlukin IL-1,IL-18 and other mediators of inflammation which enhances chemotaxis and neutrophilia including an attack of FMF leading to episodes of inflammation (with accompanying fever) in the peritoneum, pleura, and joints; persistent subclinical inflammation is also common. The inflammatory episodes in persons with FMF lead to the excess production of amyloid A protein in the acute phase and reactant serum amyloid A with subsequent deposition in the kidneys. Only patients with specific MEFV haplotypes develop amyloidosis. Page 1 of 12
2 Clinical manifestations Episodes last for one to three days and then resolve spontaneously The intervals between episodes are irregular, ranging from one week to several months or years, and patients are asymptomatic between attacks. Patients may have a stereotypic prodrome before their attacks; it may include various constitutional and physical signs, such as restlessness at the site where the symptom is about to occur, anxiety, irritability, increased appetite, and taste alterations. vigorous exercise, emotional stress, intercurrent infections, exposure to cold, surgery, and menstruation have been associated with an attack in some patients During pregnancy, the course of FMF may worsen in about a third of the patients, improve in another third of patients, and remain unchanged in the rest. 1) Recurrent fever: It is one of the most constant characteristics, presents in almost all cases during attacks (38 to 40 C), the duration is brief, lasting between 12 hours and three days It may be the first and only symptom of FMF, especially in toddlers. FMF patients who are treated with colchicine, an acute attack may occur without fever. 2) Abdominal pain It occurs in 95% in patients, presents locally and then progress to become more generalized. It is caused by inflammation of the peritoneum, signs of peritonitis such as guarding; rebound tenderness, rigidity, and a dynamic ileus are often present. These findings can be mistaken for an acute surgical abdomen leading to diagnosis delay and sometimes even to futile operations. 3) Chest pain: It occurs in %of patients, depending on the patient s ethnic origin. (Armenian have a higher rate of pleuritic involvement compared with other ethnic groups). Page 2 of 12
3 May be due to inflammation of the pleura or referred pain from subdiaphragmatic inflammation. Manifests as unilateral chest pain that is worse with inspiration or coughing and small, transient pleural effusion. Episodes usually resolve within three days, but may last up to one week. 4) Joint pain The joint attacks are usually monoarticular, involving one of the large joints (knee, ankle, hip) The synovial fluid analysis is typically sterile, with a nucleated white cell count ranging from 200 to >100,000 white blood cells/mm 3 episodes usually lasts 24 to 48 hours, which resolve completely without leading to joint destruction, but in severely protracted cases, it can result in permanent deformity, functional limitation, osteoporosis around the affected joint, and aseptic necrosis. 5) Erysipelas-like skin lesion: It occurs in 12 to 40% The lesion is typically 10 to 35 cm 2 in area, tender, raised, and erythematous and occurs on the lower leg, ankle, or foot. Lesions may be transiently warm without associated pain or tenderness In children, it may be misdiagnosed as an infectious erysipelas or cellulitis. Recovery is spontaneous and does not require antibiotics Other rare manifestations: Exertional myalgia: involves lower limbs (thighs and calves) in children, not treated by colchicine, resolves with rest and NSAIDs Acute pericarditis: include chest pain (sharp and pleuritic, improved by sitting up and leaning forward), pericardial friction rub, and widespread ST segment elevation on electrocardiogram Page 3 of 12
4 Acute scrotum: unilateral gradual swelling of the scrotum in children. Protracted febrile myalgia: have an increased ESR but a normal serum creatine kinase level Headache and aseptic meningitis. Long-term complications: Secondary (AA) amyloidosis Small bowel obstruction Infertility DIAGNOSIS: FMF is suspected in individuals with recurrent febrile episodes accompanied by peritonitis, synovitis or pleuritis, recurrent erysipelas-like erythema, repeated laparotomies for an acute abdomen with no identifiable underlying pathology, a first-degree relative with FMF, and/or membership in an at-risk ethnic group. Genetic testing for FMF serves to support the diagnosis in patients who meet clinical criteria for FMF Six-month trial of colchicine therapy that results in a relief of attacks and recurrence after cessation of treatment. (In patients who met the clinical criteria but genetic testing was not diagnostic). Elevation of serum markers of systemic inflammation Elevated fibrinogen. Elevated C-reactive protein (CRP) Elevated serum amyloid A (SAA) protein Elevated erythrocyte sedimentation rate (ESR) Serum homocysteine and lipoprotein(a) FMF is diagnosed in patients with any of the following: 1 major criteria 2 minor criteria Page 4 of 12
5 1 minor plus 5 supportive criteria 1 minor criterion plus 4 of the first five supportive criteria Differential diagnosis: * It varies with the patient's predominant clinical features Periodic fever syndromes Systemic juvenile idiopathic arthritis/adult Still's disease Systemic vasculitis involving the abdomen Systemic rheumatic diseases Page 5 of 12
6 Infection Malignancy Goals of therapy: Prevent acute attacks. Minimize subclinical inflammation in between attacks. prevent the development and progression of amyloidosis Pharmacological treatment: Colchicine: Trade names: colchicine tabs 1mg (available in Jordan) colcine 0.5 mg tab (available in Jordan) colcrys 0.6 mg tab. Primarily effective as a prophylactic treatment for the FMF attacks. It is recommended in all patients regardless of the frequency and intensity of attacks. Use of intermittent high-dose colchicine only for treatment of acute attacks of FMF is not recommended since it does not protect from the development of amyloidosis resulting from low-grade inflammation that can occur during asymptomatic intervals MOA: affects the motility of neutrophils by reducing their deformability and elasticity. Adherence with colchicine is higher with once-daily dosing and its efficacy is the same as with splitting the dose into two divided daily doses. Colchicine dose is not split unless the patient does not tolerate once-daily dosing due to side effects, which are most commonly gastrointestinal. We generally start with a lower dose and increase the dose by 0.5 to 0.6 mg according to the patient s response and tolerance without exceeding the maximum recommended daily dose of colchicine, which is 2 mg for children under 12 years and 3 mg for adults. Page 6 of 12
7 High-dose colchicine is associated with significant side effects such as blood cytopenias, rhabdomyolysis or myopathy, peripheral neuropathy, liver failure, or severe cutaneous eruption. Dosing and administration <5 years of age: 0.5 mg/day ( 0.6 mg/day in case tablets contain 0.6 mg) years of age: 0.5 to 1 mg/day (0.6 to 1.2 mg/day in case tablets contain 0.6 mg). >10 years of age and adults, 1 to 1.5 mg/day (1.2 to 1.8 mg/day in case tablets contain 0.6 mg). The tablet can be split in half. In patients with preexisting complications (Eg. Renal amyloidosis) or greater disease activity (high frequency of attacks, long duration of each attack, involvement of multiple sites during the attack, and joint involvement), higher initial doses (up to 2 mg/day) are needed. Acute attacks: As soon as the patient recognize than an attack is coming, 0.5mg every hour for 4 doses, then 0.5mg every 2 hours for 2 doses, and then 0.5mg every 12 hours for 4 doses. Dose Adjustments: Adult Renal adjustment: CrCl 30 to 80 ml/minute: Monitor closely for adverse effects; dose reduction may be necessary. CrCl <30 ml/minute: Initial dose: 0.3 mg daily; use caution if dose titrated; monitor for adverse effects. Dialysis: 0.3 mg as a single dose; use caution if dose titrated; dosing can be increased with close monitoring; monitor for adverse effects. Not removed by dialysis Pediatric renal adjustment: Children 4 years and Adolescents: Colcrys: Oral: Page 7 of 12
8 CrCl 30 to 80 ml/minute: Monitor closely for adverse effects; dose reduction may be necessary. CrCl <30 ml/minute: Initial dose: 0.3 mg daily; use caution if dose titrated; monitor for adverse effects. Dialysis: Nondialyzable: 0.3 mg as a single dose; use caution if dose titrated; dosing can be increased with close monitoring; monitor for adverse effects Adult and pediatric Hepatic Impairment: Mild to moderate impairment: Use caution; monitor closely for adverse effects. Severe impairment: There is no specific dosage adjustment provided in the manufacturer's labeling; dosage adjustment should be considered. Monitoring Patients should be followed closely for three to six months to observe its therapeutic effect on attack frequency and severity. Laboratory monitoring: Complete blood count (CBC): to assess for leukopenia. Erythrocyte sedimentation rate (ESR) C-reactive protein (CRP) Serum amyloid A (SAA). Urine for proteinuria, which may be the first sign of renal amyloidosis. Liver and kidney function tests annually. Safety: It s not likely to be effective in patients who already have chronic renal failure, since irreversible glomerular injury is probably present It s safe even when given continually over decades Side effects, most commonly gastrointestinal (such as diarrhea, nausea, vomiting), are uncommon at low doses (0.5 to 1.2 mg per day), even when given continuously over years. Page 8 of 12
9 Less common (<1 %) side effects include bone marrow suppression, hepatotoxicity, and myotoxicity. Pregnancy category C: The benefits of continued colchicine therapy through pregnancy outweigh any risks to the fetus Safe in Lactating women. Interactions: Drug interactions: Digoxin, folic acid: may increase the serum concentration of Colchicine. Multivitamins/Fluoride: colchicine may decrease absorption of cyanocobalamin (vitamin B12). Food interactions: Grapefruit Juice: May increase the serum concentration of Colchicine. Risk X: Avoid combination. Reassessment: When the patient is stable, with no attacks for more than 5 years, and no elevation in acute phase reactants (eg,serum amyloid A protein, C-reactive protein) dose reduction could be considered after expert consultation and with continued monitoring. In rare cases of heterozygous FMF patients who are asymptomatic for several (more than five) years and do not display elevated acute phase reactants, it may be possible to discontinue colchicine Patients who fail to respond to colchicine fall into one of the following categories: Patients whose symptoms are not due to FMF: ( tumor necrosis factor (TNF) receptor-1 associated periodic syndrome (TRAPS)) Patients who are nonadherent or incompletely adherent with therapy Page 9 of 12
10 Colchicine-resistant FMF: patients who still experience frequent attacks despite the maximal tolerable dose of colchicine (up to 3 mg daily in adults and 2 mg in children) are considered to have crfm. crfmf: is the occurrence of one or more attacks each month despite receiving the maximally tolerated dose for at least six months Patient Education: Colchicine is not a pain medication and should not be used to relieve other causes of pain. Take this medication by mouth with or without food, exactly as directed by your doctor. For pediatric, we can crush tablets Taking more than the recommended dose may not increase this drug's effectiveness and may increase your risk for side effects. Colchicine resistance or intolerance: We give concomitant colchicine at a tolerable dose (or approximately 1.5 to 2 mg daily) in order to prevent amyloidosis. 1) Interleukin-1 inhibition A-Canakinumab ( Ilaris ) generally preferred due to its efficacy and convenience since it is given as a subcutaneous injection every four to eight weeks. It s a human immunoglobulin G (IgG) antibody directed against IL-1-beta SubQ: 150 mg (wt > 40 Kg), 2mg\Kg (wt <= 40 Kg) every 4 weeks. May increase the dose to 300 mg (>40Kg) or 3mg\Kg (wt <=40Kg) every 4 weeks if response is inadequate. Does not need renal nor hepatic adjustments. B-Anakinra (Kineret ) is a recombinant version of the IL-1 receptor antagonist Page 10 of 12
11 SubQ 100 mg once daily Dose Adjustment Renaly: CrCl < 30 mg\min or ESRD consider dosing every other day. Doesn't need hepatic adjustment. C- Rilonacept (Acralyst ) Is a dimeric fusion protein consisting of the extracellular portions of the human IL-1 receptor and the Fc region of human IgG1 that binds and neutralizes IL-1 Dose: SubQ initial dose 320mg as two separate injections maintenance dose: 160mg once weekly Cat C in pregnancy Does not need dose adjustment. Other agents: Thalidomide (Thalomid ) Etanercept (Enbrel ) Adalimumab (Humira ) Infliximab (Remicade ) Tocilizumab (Actemra _) MANAGEMENT OF SPECIFIC FEATURES: Chronic arthritis: sulfasalazine and/or methotrexate Protracted febrile myalgia: prednisone 1 mg/kg daily for one to two weeks and then decrease the dose gradually over four to eight weeks. Exertional myalgia: Exercise-induced myalgia improves with resting or treatment with (NSAIDs). NSAIDs may be given once the patient experiences muscle pain, and the symptoms typically resolve with a single dose and in some cases acetaminophen is effective too. Page 11 of 12
12 References: Eldad Ben,Chetrit, MD. (2018). Clinical manifestations and diagnosis of familial Mediterranean fever. Monica Ramirez Curtis, MD, MPH, Shilpa Grover, MD, MPH, AGAF (Ed.), UpToDate. Retrieved October,1,2018,from Eldad Ben-Chetrit, MD. (2018). Management of familial Mediterranean fever. Monica Ramirez Curtis, MD, MPH, Shilpa Grover, MD, MPH, AGAF (Ed.), UpToDate. Retrieved October,1,2018,from Colchicine.Lexi-drugs.Lexicomp.Lolters Kluwer Health,Inc.Riverwoods,IL.Available at Accessed September 30,2018 Done By:Pharm D students: Ranya mohammed & Sara Dabbas Supervised by : Pharm D Eshraq Al-abweeny Page 12 of 12
FAMILIAL MEDITERRANEAN FEVER (FMF) RAKAN TELFAH not MD, not PHD
FAMILIAL MEDITERRANEAN FEVER (FMF) RAKAN TELFAH not MD, not PHD FMF Is a hereditary autoinflammatory disease caused by mutations in Mediterranean fever gene (MEFV). It is inherited in an autosomal recessive
More informationFamilial Mediterranean Fever
Familial Mediterranean Fever FMF most often occurs in individuals of Mediterranean and Middle Eastern descent, and the first episodes typically begin in childhood Fast Facts FMF causes episodic fevers
More informationFamilial Mediterranean Fever. By:Ismaeel Qattam
Familial Mediterranean Fever By:Ismaeel Qattam FMF : It s characterized by auto inflammatory condition that causes recurrent fevers and painful inflammation of the abdomen, lungs, joints, etc. It s an
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard HGNC ID: 6998 OMIM ID: 134610 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does
More informationTNF Receptor Associated Periodic Syndrome (TRAPS)
https://www.printo.it/pediatric-rheumatology/gb/intro TNF Receptor Associated Periodic Syndrome (TRAPS) Version of 2016 1. WHAT IS TRAPS 1.1 What is it? TRAPS is an inflammatory disease characterised by
More informationFamilial Mediterranean Fever
www.printo.it/pediatric-rheumatology/gb/intro Familial Mediterranean Fever Version of 2016 1. WHAT IS FMF 1.1 What is it? Familial Mediterranean Fever (FMF) is a genetically transmitted disease. Patients
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationCryopyrin Associated Periodic Syndromes (CAPS) (CINCA/Muckle Wells/FCAS)
https://www.printo.it/pediatric-rheumatology/gb/intro Cryopyrin Associated Periodic Syndromes (CAPS) (CINCA/Muckle Wells/FCAS) Version of 2016 1. WHAT IS CAPS 1.1 What is it? Cryopyrin-Associated Periodic
More informationDrug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
More informationFMF patient with Muscle Pain. Soad Haj Yahia Sheba Medical Center Tel Hashomer -Israel
FMF patient with Muscle Pain Soad Haj Yahia Sheba Medical Center Tel Hashomer -Israel Introduction FMF Familial Mediterranean Fever -Auto inflammatory disease caused by mutations in MEFV gene. -Autosomal
More informationFamilial Mediterranean Fever. For. Professor Brutlag BIO84 16 March 2011
Familial Mediterranean Fever For Professor Brutlag BIO84 16 March 2011 2 Three months ago, I received the results are ready e-mail I had been eagerly anticipating since the moment I spit into that infamous
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress AUTO-INFLAMMATORY (HYPER-INFLAMMATORY) SYNDROMES AN UPDATE Dr. John M. Angles BVSc, BSc(Vet), MVS, PhD, MACVSc,
More informationUmbrella study design in patients with Hereditary Periodic Fevers, an orphan autoimmune disease. Karine Lheritier 15 June 2016 PSI Immunology meeting
Umbrella study design in patients with Hereditary Periodic Fevers, an orphan autoimmune disease Karine Lheritier 15 June 2016 PSI Immunology meeting Outline Hereditary Periodic Fevers Canakinumab Study
More informationMEDICAL POLICY I. POLICY POLICY TITLE POLICY NUMBER CANAKINUMAB (ILARIS ) MP-2.147
Original Issue Date (Created): May 1, 2010 Most Recent Review Date (Revised): March 25, 2014 Effective Date: June 1, 2014 I. POLICY Preauthorization is required for injectable Canakinumab (Ilaris ): Note:
More informationMevalonate Kinase Deficiency (MKD), or Hyper IGD Syndrome
www.printo.it/pediatric-rheumatology/gb/intro Mevalonate Kinase Deficiency (MKD), or Hyper IGD Syndrome Version of 2016 1. WHAT IS MKD 1.1 What is it? Mevalonate kinase deficiency is a genetic disease.
More informationDisclosures. Learning Objectives. Periodic Fever Syndromes. Innate Immune System. Our Immune System
39 th National Conference on Pediatric Health Care March 19-22, 2018 CHICAGO Disclosures Periodic Fevers in Children: Solving the puzzle leading toward treatment No disclosures to report Betsy Roth Wojcicki
More informationMore Than Growing Pains: Therapeutic Review of Juvenile Idiopathic Arthritis (JIA)
More Than Growing Pains: Therapeutic Review of Juvenile Idiopathic Arthritis (JIA) Brittany A. Bruch, PharmD PGY2 Ambulatory Care Pharmacy Resident University of Iowa Hospitals and Clinics November 10,
More informationTumor Necrosis Factor-alpha Antagonists in the Treatment of Secondary Amyloidosis. Gulen Hatemi Istanbul University
Tumor Necrosis Factor-alpha Antagonists in the Treatment of Secondary Amyloidosis Gulen Hatemi Istanbul University TNF-alpha blockage in AA amyloidosis TNF induces SAA production in hepatocytes during
More informationRilonacept for cryopyrin associated periodic syndromes
Rilonacept for cryopyrin associated periodic syndromes August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationPsoriatic Arthritis- Secondary Care
Psoriatic Arthritis- Secondary Care Our Psoriatic Arthritis: First Line Treatments information sheet gives information on the treatments that can be prescribed by a GP, or that might be prescribed if the
More informationMMS Pharmacology Lecture 2. Antirheumatic drugs. Dr Sura Al Zoubi
MMS Pharmacology Lecture 2 Antirheumatic drugs Dr Sura Al Zoubi Revision Rheumatoid Arthritis Definition (RA): is the most common systemic inflammatory disease characterized by symmetrical inflammation
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationPatient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationCases from the Clinic Maryland ACP Meeting January 30, 2016
Cases from the Clinic Maryland ACP Meeting January 30, 2016 Bimal Ashar, MD, FACP D. William Schlott, MD Associate Professor of Medicine Johns Hopkins University School of Medicine 1 CASE 1: GK 46-year-old
More informationClinical Study Serum Amyloid A Level in Egyptian Children with Familial Mediterranean Fever
International Rheumatology Volume 2016, Article ID 7354018, 6 pages http://dx.doi.org/10.1155/2016/7354018 Clinical Study Serum Amyloid A Level in Egyptian Children with Familial Mediterranean Fever Hala
More informationClinical Policy: Tocilizumab (Actemra) Reference Number: ERX.SPMN.44
Clinical Policy: (Actemra) Reference Number: ERX.SPMN.44 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS DRUG
SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS Anakinra Kineret 100mg/0.67mg pre-filled syringe For the treatment of systemic juvenile idiopathic arthritis in patients who meet the following criteria; Patient
More informationANNEX III AMENDMENTS TO THE SUMMARIES OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLETS
ANNEX III AMENDMENTS TO THE SUMMARIES OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLETS 41 AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS FOR CABERGOLINE CONTAINING
More informationFamilial Mediterranean Fever
https://www.printo.it/pediatric-rheumatology/gb/intro Familial Mediterranean Fever Version of 2016 2. DIAGNOSIS AND TREATMENT 2.1 How is it diagnosed? Generally the following approach is followed: Clinical
More informationClinical Policy: Canakinumab (Ilaris) Reference Number: ERX.SPA.04 Effective Date:
Clinical Policy: (Ilaris) Reference Number: ERX.SPA.04 Effective Date: 04.01.17 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationGout Treatment Guidelines
Gout Treatment Guidelines Gout is a disorder that manifests as a spectrum of clinical and pathologic features built on a foundation of an excess body burden of uric acid, manifested in part by hyperuricemia,
More informationDefinition Chronic autoimmune disease The body s immune system starts attacking itself Can affect most organs and tissues in the body Brain, lungs, he
LIVING WITH SYSTEMIC LUPUS ERYTHEMATOSUS Stacy Kennedy, M.D.,M.B.A. Rowan Diagnostic Clinic Salisbury, N.C. May 11, 2013 Agenda What is lupus Who is affected Causes of lupus Symptoms and organ involvement
More information1.1. Tocilizumab and necrotising fasciitis
1.1. Tocilizumab and necrotising fasciitis Introduction Tocilizumab (RoActemra ) binds specifically to both soluble and membranebound interleukin-6 (IL-6) receptors. IL-6 is a pleiotropic pro-inflammatory
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationSiklos (hydroxyurea) NEW PRODUCT SLIDESHOW
Siklos (hydroxyurea) NEW PRODUCT SLIDESHOW Introduction Brand name: Siklos Generic name: Hydroxyurea Pharmacological class: Antimetabolite Strength and Formulation: 100mg, 1000mg+; tabs; +triple-scored
More informationBackground 11/8/2011. Disclosure. Hereditary Periodic Fever Syndromes Mutations in Idiopathic Acute Recurrent Pericarditis.
Mutations in Idiopathic Acute Recurrent Pericarditis Disclosure I have no relevant financial relationships to disclose Guillaume Geri, Pierre Hausfater, Catherine Dodé, Zahir Amoura, Jean-Charles Piette,
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Ilaris) Reference Number: CP.PHAR.246 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationPsoriatic Arthritis- Second Line Treatments
Psoriatic Arthritis- Second Line Treatments Second line treatments for Psoriatic Arthritis (PsA) are usually prescribed by a Rheumatologist, Dermatologist, or in a combined clinic where both the Dermatologist
More information2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J.
Making Room for Rheumatology James J. Nocton, MD Disclosures I have nothing to disclose Rheumatic Diseases of Childhood Juvenile Idiopathic Arthritis (JIA) Systemic Lupus Erythematosus (SLE) Juvenile Dermatomyositis
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 6 Last Review Date: December 8, 2017 Orencia Description Orencia (abatacept)
More informationMEDICATION GUIDE. (tocilizumab)
MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Read this Medication Guide before you start ACTEMRA and before each infusion. There may be new information. This Medication Guide does not take the place
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 04/09/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: 09/05/18 ARCHIVE DATE:
ILARIS (canakinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationPeriodic Fever With Apthous Pharyngitis Adenitis (PFAPA)
www.printo.it/pediatric-rheumatology/za_gb/intro Periodic Fever With Apthous Pharyngitis Adenitis (PFAPA) Version of 2016 1. WHAT IS PFAPA 1.1 What is it? PFAPA stands for Periodic Fever Adenitis Pharyngitis
More informationAzathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS
Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Only valid for adult patients Azathioprine must be at a dose of at least
More informationTo help you with terms and abbreviations used in this document that may be unfamiliar to you, a glossary is provided on the last pages.
ARTHRITIS CONSUMER EXPERTS 910B RICHARDS STREET VANCOUVER BC V6B 3C1 CANADA T: 604.974-1366 F: 604.974-1377 WWW.ARTHRITISCONSUMEREXPERTS.ORG Arthritis Consumer Experts In Health Care and Research Decision-making
More informationKELFER Deferiprone. COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg
KELFER Deferiprone COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg KELFER-500 Capsules Each capsule contains Deferiprone 500 mg DOSAGE FORM Capsules PHARMACOLOGY Pharmacodynamics
More informationAutoimmunity and autoinflammation
Autoimmunity and autoinflammation Primary immunodeficiencies Autoimmunity and autoinflammation 1 Primary immunodeficiencies List of some common abbreviations APECED CAPS CGD CINCA CRMO CVID FCAS FMF HIDS
More informationAnti-Tumor Necrosis Factor (Anti-TNF)
Anti-Tumor Necrosis Factor (Anti-TNF) 110465 Anti-TNF.indd 1 9/20/16 9:01 AM s About your medicine Anti-tumor necrosis factor (anti-tnf) is a type of medicine called biologic agent that targets substance
More informationDRUG THERAPY
www.pediatric-rheumathology.printo.it DRUG THERAPY NSAIDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS They are symptomatic anti-inflammatory, anti febrile (fever) and analgesic (pain reducing) medications. Symptomatic
More informationEDEMA IN A PATIENT WITH RECURRENT RESPIRATORY INFECTIONS - Case Report
EDEMA IN A PATIENT WITH RECURRENT RESPIRATORY INFECTIONS - Case Report Alain SOUPART, MD, PhD, FACP.hon Department of General Internal Medicine, Jolimont/Tubize and Erasmus University Hospital, Free University
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Community Plan Medical Benefit Drug Policy ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION Policy Number: CS2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationACTEMRA Risk Mitigation Strategy Presenter Name, Degree
ACTEMRA Risk Mitigation Strategy Presenter Name, Degree Medical Science Liaison Genentech, Inc. 1 Indications and Dosage Rheumatoid Arthritis (RA) (1 of 2) Indication in RA ACTEMRA (tocilizumab) is indicated
More informationNEOFEN 60 mg suppository
PACKAGE LEAFLET: INFORMATION FOR THE USER NEOFEN 60 mg suppository IBUPROFEN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationFamilial Mediterranean Fever in a Sample of Iraqi Patients
FAMILIAL THE IRAQI MEDITERRANEAN POSTGRADUATE FEVER MEDICAL JOURNAL VOL.6, NO.2, 2007 Familial Mediterranean Fever in a Sample of Iraqi Patients Ali Abdul Kadhim Al Sultany ABSTRACT: BACKGROUND: Up to
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationAmyloidosis (Disorder Caused by Deposition of Proteins [Amyloid] in Various Organs) Basics
Amyloidosis (Disorder Caused by Deposition of Proteins [Amyloid] in Various Organs) Basics OVERVIEW A group of conditions of differing cause in which insoluble proteins (amyloid) are deposited outside
More informationSuccessful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever
Case report Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever Akinori Nakamura Masayuki Matsuda Ko-ichi Tazawa Yasuhiro Shimojima Shu-ichi
More informationRheumatic Fever And Post-streptococcal Reactive Arthritis
www.printo.it/pediatric-rheumatology/gb/intro Rheumatic Fever And Post-streptococcal Reactive Arthritis Version of 2016 1. WHAT IS RHEUMATIC FEVER 1.1 What is it? Rheumatic fever is a disease caused by
More informationUsing ENBREL to Treat Rheumatoid and Psoriatic Arthritis
Using ENBREL to Treat Rheumatoid and Psoriatic Arthritis Writing White Papers class Bellevue Community College TABLE OF CONTENTS TABLE OF CONTENTS...2 OVERVIEW...3 RHEUMATOID ARTHRITIS... 3 JUVENILE RHEUMATOID
More informationATHEROSCLEROSIS AMONG PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER ROLE OF COLCHICINOTHERAPY
4th Eastern European Conference on Rare Diseases and Orphan Drugs 13-14 June 2009 in Plovdiv, Bulgaria. ATHEROSCLEROSIS AMONG PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER ROLE OF COLCHICINOTHERAPY Poster
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationMEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib)
MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib) Read this Medication Guide before you start taking XELJANZ and each time you get a refill. There may be new information. This Medication Guide does not
More informationIlaris (canakinumab) (Subcutaneous)
Ilaris (canakinumab) (Subcutaneous) Last Review Date: 08/02/2018 Date of Origin: 11/07/2013 Dates Reviewed: 08/2014, 07/2015, 07/2016, 10/2016, 10/2017, 08/2018 Document Number: IC-0177 I. Length of Authorization
More informationArcalyst (rilonacept)
Arcalyst (rilonacept) Policy Number: 5.02.510 Last Review: 4/2018 Origination: 06/2013 Next Review: 4/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Arcalyst
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Canakinumab Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 5 Effective Date... 7/15/2017 Next
More informationALUNBRIG (brigatinib) Dosing Guide
ALUNBRIG (brigatinib) Dosing Guide INDICATION ALUNBRIG (brigatinib) is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of
More informationKELFER Capsules (Deferiprone)
Published on: 22 Sep 2014 KELFER Capsules (Deferiprone) Composition KELFER-250 Capsules Each capsule contains Deferiprone 250 mg KELFER-500 Capsules Each capsule contains Deferiprone 500 mg Dosage Form
More informationFive Cases of Familial Mediterranean Fever in Japan: The Relationship with MEFV Mutations
doi: 10.2169/internalmedicine.0057-17 http://internmed.jp CASE REPORT Five Cases of Familial Mediterranean Fever in Japan: The Relationship with MEFV Mutations Kazuki Kimura 1,2, Masafumi Mizooka 2, Kiyoshi
More informationInitial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapy and the Treatment
Initial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapy and the Treatment of Patients in the Midst of an Acute Gout Attack Investor
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationAlthough this presentation includes information regarding pharmaceuticals (including products under development), the information is not intended as
Although this presentation includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice. Forward-Looking
More informationMedication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013
Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,
More informationRheumatoid Arthritis. Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011
Rheumatoid Arthritis Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011 The security of experience. The power of innovation. www.rgare.com Case Study
More informationWelcome to Juvenile Rheumatoid Arthritis or JRA, by Connie Martin, MS, RDN; Claire Stephens, MS, RDN; and Lolita McLean, MPH, RDN...
Welcome to Juvenile Rheumatoid Arthritis or JRA, by Connie Martin, MS, RDN; Claire Stephens, MS, RDN; and Lolita McLean, MPH, RDN...all of Alabama s Children s Rehabilitation Service, part of the Alabama
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More informationRheumatoid Arthritis
Rheumatoid Arthritis What is rheumatoid arthritis? Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Rheumatoid arthritis can also cause inflammation of
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Gout i Gout has a worldwide distribution. In the United Kingdom from 2000 to 2007, the estimated occurrence of gout is 5.9% in
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
More informationNOTOPAIN CAPLETS. Diclofenac Sodium + Paracetamol. Composition. Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg.
NOTOPAIN CAPLETS Diclofenac Sodium + Paracetamol Composition Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg Pharmacology Phamacodynamics Diclofenac relieves pain and inflammation
More informationUNDERSTANDING SYSTEMIC LUPUS ERYTHEMATOSUS
UNDERSTANDING SYSTEMIC LUPUS ERYTHEMATOSUS Stacy Kennedy, M.D.,M.B.A. October 20, 2012 Agenda What is lupus Who is affected Causes of lupus Symptoms and organ involvement Diagnosis Treatment Pregnancy
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION TOFACITINIB (Xeljanz Pfizer Canada Inc.) Indication: Rheumatoid Arthritis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that tofacitinib be listed, in combination
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 6 Last Review Date: December 8, 2017 Stelara Description Stelara (ustekinumab)
More informationRheumatoid Arthritis. By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University
Rheumatoid Arthritis By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University Introduction RA is a Chronic, Systemic, Inflammatory disorder of unknown etiology
More information(sunitinib malate) for Kidney Cancer
Sutent (sunitinib malate) for Kidney Cancer Sutent is a medication used to treat adult patients with kidney cancer that has been surgically removed and at high risk of recurrence, or advanced kidney cancer
More information